Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole SodiumCategory 1.1 Ne...

HONG KONG, 17 July 2013 – Sihuan Pharmaceutical Holdings Group Ltd. announced that Anaprazole Sodium, a Category 1.1 new drug received the Approval for Clinical Studies from the State Food and Drug Administration (“SFDA”) of the People’s Republic...

Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole SodiumCategory 1.1 New Drug Clinical Studies
2015-07-14
CFDA Accepts Application for Clinical Trial Approval for Sihuan Pharmaceutical’s Self-Developed Category 1.1 Innovative

At the end of June 2015, Shandong Xuanzhu Pharma Co., Ltd. (“Shandong XuanZhu”), the Group’s innovative drug research and development division has submitted an Investigational New Drug application ...

2014-12-23
Congrats to Beijing Sihuan on Receiving the Certificate of New Technology and New Product by Zhongguancun Science Park

On December 15, 2014, ZhongguancunScience Park announced the recipients of the Certificate of New Technology and New Product (Service), Beijing Sihuan Pharmaceutical Co., Ltd.was awarded the Certifica...

2014-12-23
Congrats to Beijing Sihuan on Winning Innovation Achievement Award of 2014 Product Quality Innovation and Contribution A

On December 18, 2014, Beijing ProductsEvaluation Center announced the recipients of the 2014 Product Quality Innovation and Contribution Award, Beijing SihuanPharmaceutical Co., Ltd. was granted with ...

2014-12-02
Congrats to Beijing Sihuan on Winning Product Excellence Award of “Science & Technology Innovation Award 2014”

On November 28, the “Science & Technology Innovation Award 2014” organized by Beijing Enterprise Evaluation Association was successfully concluded, Beijing Sihuan pharmaceutical co., Ltd.

2014-11-28
Xuanzhu Pharma Received the Formal Letter from U.S. FDA on Approval of Pirotinib to Start Clinical Trials

On November 27 (November 26, U.S. time), Xuanzhu Pharma Co., Ltd., a wholly-owned subsidiary of Sihuan Pharmaceutical Holdings Group Ltd., received the formal letter from the U.S. FDA that formally approved the anti-tumor patented new drug Pirotinib (KBP5209) to enter into clinical trials.

Total 8 Pages  First page  Page up  Page down  Last page

Select

  • 2015
  • 2014
  • 2013
  • 2012